Gout, a painful form of inflammatory arthritis, is poised to become far more common in the coming decades. According to projections, the number of cases globally is expected to rise significantly over the next twenty-five years, driven by aging populations, obesity, and lifestyle factors. In the United States alone, over 9 million people have already been diagnosed with gout, and an even larger group—44 million people—have uric acid levels above the normal range, putting them at risk for the disease.
Current treatments, primarily oral xanthine oxidase inhibitors (XOIs), are effective for many but not all. Approximately 3% to 5% of patients cannot tolerate them, and they carry boxed warnings for cardiovascular risk. Other side effects include severe gastrointestinal issues, kidney toxicity, and cardiovascular problems, especially with long-term or high-dose use. Additionally, some therapies initially trigger more gout flare-ups, discouraging patient adherence. These limitations create a significant unmet need for safer, better-tolerated options.
XORTX Therapeutics Inc. (NASDAQ: XRTX), a late-stage clinical pharmaceutical company, is developing XORLO™, a proprietary formulation of oxypurinol designed to overcome these challenges. XORLO utilizes a liposomal delivery system to enhance oral absorption, allowing for lower total daily doses and reduced toxic-level exposure. The company says this approach minimizes the severe gastrointestinal side effects associated with high-dose traditional therapies while effectively lowering uric acid.
XORTX is making tangible progress toward bringing XORLO to market. The company recently announcing the launch of drug material and tablet manufacturing to support a planned two-part clinical study, XRX-OXY-102. This trial is based on positive prior clinical results and discussions with the FDA. Contract production of pure oxypurinol, the active ingredient in XORLO, has already begun using XORTX’s proprietary synthetic pathway, and the company is working with its contract manufacturing partner toward commercial drug batches.
Regulatory milestones are also in sight. XORTX is working toward a new drug application submission to the FDA for XORLO. The company has prepared a new Investigational New Drug (IND) application for submission in the fourth quarter of 2026, describing its clinical development plan. Once the two-part clinical trial is complete, XORTX intends to request a pre-NDA meeting and prepare an NDA submission, targeting a filing in about one year. The company estimates XORLO could have a market opportunity of $700 million annually.
“Our planned IND submission to the FDA next quarter is a defining step for the XRx-026 program,” said Allen Davidoff, Co-CEO of XORTX. “It reflects the strength of our prior clinical results and moves us closer to potentially offering gout patients a differentiated treatment option.”
For patients and investors, the implications are significant. If successful, XORLO could provide a better-tolerated alternative for the millions who cannot take current medications or struggle with side effects. As gout prevalence climbs, the need for innovative therapies will only grow. XORTX’s progress will be closely watched by the biotech industry and those affected by this chronic disease. The original release can be viewed on www.newmediawire.com.
